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cancers.Optimized NGS panel and data analysis
enable high sensitivity of detecting
colon and lung cancer associated
mutations from plasmaLina Ma, Feng Zhang, Qing Xu, Xiannian Tang,
Mao Mao WuXi AppTec, Shanghai, ChinaTracking tumor-associated mutation in plasma can serve
as biomarkers to facilitate cancer diagnosis and provide
guidance for target therapy. The intrinsic low abundance
and short fragments of circulating cell-free tumor DNA
(cfDNA) make the mutation detection from plasma a
challenging task. Next Generation Sequencing (NGS) al-
lows high throughput mutation analysis of cancer genes
by massively parallel sequencing. Ion Ampliseq panel is
able to construct the library with as little as 10ng DNA,
suitable for the limited amount from cfDNA. However,
the commercial Ampliseq panel together with the TVC
(Ion Torrent variant caller software) analysis was mainly
designed for mutation detection from FFPE samples. The
sensitivity is not good enough for cfDNA mutation
detection based on our assessment.
Here we have established a strategy to detect so-
matic mutations of colon and lung cancer with plasma
based on AmpliSeq Ion Torrent System. Firstly, a colon
and lung panel was designed for small amplicons (less
than 140bp), so as to better capture small cfDNA
fragments as effective templates in multiplex PCR. The
ampliﬁcation test shows that our panel produced
amplicons with a good uniformity when applied to
cfDNA. Secondly, background noise analysis has shown
the noise unevenly distributed along the genome and
error hotspots repeatedly showed up among different
samples. Based on the features of background noise, we
have developed a new algorithm to distinguish low
level mutations from sequencing errors, which makes
use of sequencing data from healthy individuals as
reference to estimate the sequencing error proﬁle. A
reliability of the mutant allele at each position was
evaluated by statistical test of background noise versus
signal. To evaluate the detection limit of our approach,
a cell line mix which contains several mutations at
different level of mutations was examined. Digital
droplet PCR (ddPCR) assay was used to conﬁrm the
allele frequency of each mutation. This analysis dem-
onstrates that our approach is able to call mutations at
a fractional abundance of 0.15-0.3%, depending on the
genomic positions. The allele frequency from
sequencing result correlates well with ddPCR result(R2¼0.90). Moreover, the analytical speciﬁcity is higher
than 99% with such detection limit.
To test the clinical performance of our method, cfDNA
from non-small cell lung cancer (NSCLC) patients was
used. With 10ng cfDNA, this method is able to call mu-
tation as low as 0.5%, the lowest clinical sample tested,
while with the commercial kit and variant analysis
software, it only calls at 5%. The detection limit of our
approach for clinical cfDNA sample will be determined
with more tests.
Ion Torrent PGM has been widely used in clinical
environment, because of its cost and time effective way
compatible with clinical practice. In this proof-of-concept
study, our strategy comprised of an optimized panel
suitable for cfDNA and a novel variant calling algorithm
signiﬁcantly improves the detection limit of the PGM
platform, making it possible to detect low abundant
mutations from plasma. We envision this approach could
have utility for patient stratiﬁcation, monitoring
response to therapies and detection of relapse.Constitution of ALK fusion variants in
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Introduction: The purpose of the study is to investigate
the constitution of anaplastic lymphoma kinase (ALK)
fusion variants in East Asian lung adenocarcinoma
(LUAC) patients and to provide instructional data for the
variants that should be included in the companion
diagnostic assay to screen for ALK positive patients.
Methods: From June 2014 to August 2015, 158 ALK
fusion positive formalin-ﬁxed, parafﬁn-embedded
(FFPE) samples were identiﬁed, including 3 patient-
derived xenograft (PDX) tissues and 155 resected or ﬁne
needle aspiration (FNA) tissues, all derived from Korean
or Chinese patients. Either puriﬁed RNA or crude tissue
lysate from the 158 FFPE samples were analyzed by
NanoString nCounter Elements assay with a multiplexed
probe mix in a single tube targeting ALK fusion tran-
scripts including 29 known variants.
Results: Of the total 158 ALK fusion positive samples,
133 samples harbored echinoderm microtubule-
associated protein-like 4 ALK (EML4-ALK) fusion, 4 samples
